Compare Boston Scientific Corporation (BSX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs WD 40 Company — how do they compare? Boston Scientific Corporation trades at $43.5 (market cap $66.37B), while WD 40 Company trades at $248.39 (market cap $3.35B). The key difference: Boston Scientific Corporation is far larger — about 19.8× WD 40 Company's market cap, and WD 40 Company pays a 1.64% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | WDFC | |
|---|---|---|
Market Cap | $66.37B | $3.35B |
Sector | Health | Technology |
52-Week High | $108.14 | $264.91 |
52-Week Low | $42.63 | $187.52 |
Enterprise Value | $75.94B | $3.40B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
WDFC trades at $251.43, down 5.09% today but maintains a bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings of $2.33 per share, beating estimates by 47%, driven by broad-based sales growth. Valuation remains elevated with a P/E of 37.88 and P/S of 5, while profitability metrics show a net income margin of 13.22% and ROE of 11%. Recent news highlights WD-40's strong brand moat and inclusion in Zacks' Strong Buy list on July 15, 2026.
Outlook is positive given earnings momentum and brand strength, but high valuation and margin pressures from input costs pose risks. Analyst consensus is mixed with 71% hold ratings, suggesting cautious optimism. The stock offers growth potential but requires monitoring of cost management and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
